Baylor-Uganda is part of this ongoing multi-centre parallel, observational cohort study among HIV-uninfected pregnant adolescents and young women (aged 16-24) since March 2019.


This is a phase III randomised open-label clinical trial assessing virologic efficacy and safety of Dolutegravir-containing versus Efavirenz-containing ART regimens in HIV-1 infected pregnant women and their infants.

HPTN 084

HPTN 084: Phase III Double Blind Safety and Efficacy Study of Long Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women Pictures of HPTN 084 […]